Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2014-09-18 Capital/Financing Update
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
103年9月公開說明書 — 200609_3164_B011.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed public explanatory statement (公開說明書) for a cash capital increase and issuance of new shares by GenMont Biotech Inc. It includes extensive information about the company, capital structure, issuance conditions, use of funds, risk factors, financial data, and other disclosures typically required for a capital raising filing. The document is lengthy (15,000 characters) and contains substantive financial and operational details, not merely an announcement or summary. The key focus is on the issuance of new shares through cash capital increase, which aligns with a Capital/Financing Update filing. There is no indication that this is an annual report, earnings release, or other report types. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-09-18 Chinese
103年9月公開說明書 — 200408_3164_B04.doc
Share Issue/Capital Change Classification · 88% confidence The document is a full public prospectus (簡式公開說明書) detailing a cash capital increase issuance of new ordinary shares by GenMont Biotech Inc., including share quantities, issuance price, use of proceeds, shareholder subscription arrangements, capital structure changes, and detailed prospectus chapters. This clearly corresponds to an announcement and documentation of a new share issue / capital change. It is not a report publication announcement or a financial report like an annual or interim report, but rather the primary issuance prospectus itself. Therefore, it falls under the “Share Issue/Capital Change” category (SHA).
2014-09-18 Chinese
103年9月公開說明書 — 200405_3164_B04.doc
Share Issue/Capital Change Classification · 95% confidence The document is a detailed "簡式公開說明書" (prospectus) for a cash capital increase and issuance of 5,000,000 new shares by GenMont Biotech. It provides comprehensive information on share issuance terms, capital structure before/after issuance, use of proceeds, corporate background, board and shareholder details, and financial statements—all characteristic of a new share issue filing. This falls squarely under the “Share Issue/Capital Change” category (SHA).
2014-09-18 Chinese
103年9月公開說明書 — 200404_3164_B011.doc
Share Issue/Capital Change Classification · 95% confidence The document is a detailed “簡式公開說明書” (simplified prospectus) for a cash capital increase by issuing 5,000,000 new shares and outlines the terms, use of proceeds, corporate organization, and financial details specifically related to the share issuance. This matches the definition of a share issue/capital change filing. Therefore, it is classified as SHA (Share Issue/Capital Change).
2014-09-18 Chinese
103年9月公開說明書 — 200305_233525_B07.doc
Share Issue/Capital Change Classification · 75% confidence The document is a full “公開說明書” (prospectus) for GenMont Biotech’s application to register shares on the OTC board, detailing the share issuance, capital structure, financials, risk factors and use of proceeds. It is not merely a brief announcement or certification but a comprehensive offering document. Under our taxonomy, this corresponds to a share issue / capital change filing.
2014-09-18 Chinese
103年08月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, supervisors, and executives, with specific data on stock types, holdings at different times, increases and decreases in shares, and related notes. The content focuses on personal share transactions and holdings by company directors and executives. There is no indication of financial results, management discussion, legal proceedings, or other report types. The document is not a report publication announcement or a certification. Therefore, it fits the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades).
2014-09-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.